<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733757</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE - 03409512.2.0000.5149</org_study_id>
    <nct_id>NCT02733757</nct_id>
  </id_info>
  <brief_title>Clonidine Added Lidocaine in Intraocular Pressure and Hemodynamics Ocular in Sub-Tenon's and Peribulbar Anesthesia</brief_title>
  <official_title>Effects of Clonidine Added to Lidocaine in Sub-Tenon's and Peribulbar Anesthesia: Assessments of Intraocular Pressure (IOP), Ocular Perfusion Pressure (OPP) and Ocular Pulse Amplitude (OPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Espirito Santo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regional anesthesia in orbit can reduce ocular blood flow, increase in intraocular pressure&#xD;
      (IOP) or the pharmacological action of local anesthetics. This study was conduced to evaluate&#xD;
      the effects of clonidine added to lidocaine in IOP, ocular perfusion pressure (PPO) and&#xD;
      ocular pulse amplitude (OPA) in patients undergoing cataract surgery under sub-Tenon's and&#xD;
      peribulbar anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective randomized and double blind clinical study, involving 80 patients with&#xD;
      ages from 30 to 86 years old, ASA I and II, both genders. The patients were randomly divided&#xD;
      into 4 groups of 20 patients, and then were administered in control sub-Tenon's group 5 mL of&#xD;
      2% lidocaine with 1 mL of 0.9% sodium chloride solution; in sub-Tenon's group clonidine, 5 mL&#xD;
      of 2% lidocaine associated with 1 µg/kg of clonidine diluted in 1 mL 0.9% sodium chloride&#xD;
      solution. In the peribulbar anesthesia, the control group with 6 mL of 2% lidocaine and 1 mL&#xD;
      of 0.9% sodium chloride solution, and peribulbar group clonidine, 6 mL of 2% lidocaine&#xD;
      associated with 1 µg/kg of clonidine diluted in 1 mL 0.9% sodium chloride solution. Were&#xD;
      evaluated the systemic hemodynamic variables; IOP and OPA measurements according the dynamic&#xD;
      contour tonometer (DCT) and calculation of OPP, prior to the blockade (M0), and one (M1),&#xD;
      five (5) and ten minutes (M10) after the injection of the anesthetic solutions. Complications&#xD;
      related to the sub-Tenon's and peribulbar anesthesia were recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>Within 10 minutes before the surgery procedure</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sub-Tenon's group control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>2% Lidocaine without epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Tenon's group clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peribulbar group control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>2% Lidocaine without epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peribulbar group clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Clonidine 1 µg/kg plus 2% lidocaine</description>
    <arm_group_label>Peribulbar group clonidine</arm_group_label>
    <arm_group_label>Sub-Tenon's group clonidine</arm_group_label>
    <other_name>Atensine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults between 30 and 86 years old&#xD;
&#xD;
          -  Both genders&#xD;
&#xD;
          -  Physical status ASA (American Society of Anesthesiologists) I and II&#xD;
&#xD;
          -  Cooperative patients undergoing cataract surgery by phacoemulsification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with communication difficulties&#xD;
&#xD;
          -  Allergic to any medication protocol&#xD;
&#xD;
          -  Chronic therapy with clonidine&#xD;
&#xD;
          -  In use of antihypertensive medication&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Previous surgery in the same eye&#xD;
&#xD;
          -  Abnormalities in coagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sigmar Cabral, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Espírito Santo, Vitória</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renato Gomez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Minas Gerais, Belo Horizonte</affiliation>
  </overall_official>
  <reference>
    <citation>Pianka P, Weintraub-Padova H, Lazar M, Geyer O. Effect of sub-Tenon's and peribulbar anesthesia on intraocular pressure and ocular pulse amplitude. J Cataract Refract Surg. 2001 Aug;27(8):1221-6.</citation>
    <PMID>11524193</PMID>
  </reference>
  <reference>
    <citation>Watkins R, Beigi B, Yates M, Chang B, Linardos E. Intraocular pressure and pulsatile ocular blood flow after retrobulbar and peribulbar anaesthesia. Br J Ophthalmol. 2001 Jul;85(7):796-8.</citation>
    <PMID>11423451</PMID>
  </reference>
  <reference>
    <citation>Cabral SA, Carraretto AR, Brocco MC, Abreu Baptista JF, Gomez RS. Effect of clonidine added to lidocaine for sub-Tenon's (episcleral) anesthesia in cataract surgery. J Anesth. 2014 Feb;28(1):70-5.</citation>
    <PMID>23797624</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <results_first_submitted>August 11, 2020</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Renato Santiago Gomez</investigator_full_name>
    <investigator_title>Head of surgery department of the medical school of the Federal University of Minas Gerais</investigator_title>
  </responsible_party>
  <keyword>Clonidine</keyword>
  <keyword>Sub-Tenon's and Peribulbar block</keyword>
  <keyword>IOP</keyword>
  <keyword>OPP</keyword>
  <keyword>OPA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sub-Tenon's Group Control</title>
          <description>2% Lidocaine without epinephrine</description>
        </group>
        <group group_id="P2">
          <title>Sub-Tenon's Group Clonidine</title>
          <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg&#xD;
Clonidine: Clonidine 1 µg/kg plus 2% lidocaine</description>
        </group>
        <group group_id="P3">
          <title>Peribulbar Group Control</title>
          <description>2% Lidocaine without epinephrine</description>
        </group>
        <group group_id="P4">
          <title>Peribulbar Group Clonidine</title>
          <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg&#xD;
Clonidine: Clonidine 1 µg/kg plus 2% lidocaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sub-Tenon's Group Control</title>
          <description>2% Lidocaine without epinephrine</description>
        </group>
        <group group_id="B2">
          <title>Sub-Tenon's Group Clonidine</title>
          <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg&#xD;
Clonidine: Clonidine 1 µg/kg plus 2% lidocaine</description>
        </group>
        <group group_id="B3">
          <title>Peribulbar Group Control</title>
          <description>2% Lidocaine without epinephrine</description>
        </group>
        <group group_id="B4">
          <title>Peribulbar Group Clonidine</title>
          <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg&#xD;
Clonidine: Clonidine 1 µg/kg plus 2% lidocaine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="12"/>
                    <measurement group_id="B2" value="60" spread="13"/>
                    <measurement group_id="B3" value="64" spread="14"/>
                    <measurement group_id="B4" value="62" spread="12"/>
                    <measurement group_id="B5" value="63" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP)</title>
        <time_frame>Within 10 minutes before the surgery procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sub-Tenon's Group Control</title>
            <description>2% Lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Sub-Tenon's Group Clonidine</title>
            <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg&#xD;
Clonidine: Clonidine 1 µg/kg plus 2% lidocaine</description>
          </group>
          <group group_id="O3">
            <title>Peribulbar Group Control</title>
            <description>2% Lidocaine without epinephrine</description>
          </group>
          <group group_id="O4">
            <title>Peribulbar Group Clonidine</title>
            <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg&#xD;
Clonidine: Clonidine 1 µg/kg plus 2% lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="3"/>
                    <measurement group_id="O2" value="16" spread="4"/>
                    <measurement group_id="O3" value="19" spread="3"/>
                    <measurement group_id="O4" value="16" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sub-Tenon's Group Control</title>
          <description>2% Lidocaine without epinephrine</description>
        </group>
        <group group_id="E2">
          <title>Sub-Tenon's Group Clonidine</title>
          <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg&#xD;
Clonidine: Clonidine 1 µg/kg plus 2% lidocaine</description>
        </group>
        <group group_id="E3">
          <title>Peribulbar Group Control</title>
          <description>2% Lidocaine without epinephrine</description>
        </group>
        <group group_id="E4">
          <title>Peribulbar Group Clonidine</title>
          <description>2% Lidocaine without epinephrine plus clonidine 1 µg/kg&#xD;
Clonidine: Clonidine 1 µg/kg plus 2% lidocaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Renato Gomez</name_or_title>
      <organization>Universidade federal de Minas Gerais</organization>
      <phone>553134099760</phone>
      <email>renatogomez2000@yahoo.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

